GSK Expands Treasury Stock as Share Buyback Programme Advances

An announcement from GlaxoSmithKline ( (GB:GSK) ) is now available.

GSK plc has continued its share buyback programme, repurchasing 232,912 ordinary shares on 19 December 2025 through BNP Paribas at a volume-weighted average price of 1,807.58 pence, with the shares to be held in treasury. Since the start of the current buyback phase on 30 September 2025, GSK has acquired a total of 14,554,645 shares, lifting its treasury holding to 240,019,489 shares, equivalent to 5.89% of voting rights, and leaving 4,075,425,537 shares in issue, a move that modestly concentrates remaining shareholders’ stakes and signals ongoing capital-return efforts to the market.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s overall stock score is driven by strong financial performance and favorable valuation metrics. The company’s strategic initiatives, including share buybacks and R&D investments, support its growth outlook. However, challenges in cash flow and certain market segments warrant cautious optimism.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK plc is a global biopharmaceutical company focused on developing and commercialising prescription medicines, vaccines and specialty healthcare products, with a portfolio spanning infectious diseases, respiratory conditions, immunology and oncology across international markets.

Average Trading Volume: 9,350,883

Technical Sentiment Signal: Buy

Current Market Cap: £73.51B

Learn more about GSK stock on TipRanks’ Stock Analysis page.